Espana 90 Tablet

About Espana 90 Tablet

The tablet Espana 90 contains Etoricoxib and is made by United Chemicals & Pharmaceuticals Ltd. It does not treat the underlying disease; it relieves symptoms.

There are 90 brands of Etoricoxib listed in Bangladesh. The lowest listed price is Retoz 90 mg Tablet at ৳ 1 per unit.

What is Espana 90 Tablet?

The tablet Espana 90 contains Etoricoxib and is made by United Chemicals & Pharmaceuticals Ltd. Because it is a prescription medicine, the doctor decides whether it suits you and how it should be taken. Medicines in this group are used to relieve symptoms such as pain and inflammation in a number of joint and muscle conditions. Ask your doctor or pharmacist if you are unsure about it.

Uses of Espana 90

It does not treat the underlying disease; it relieves symptoms. Espana 90 is used for symptomatic relief in several painful and inflammatory conditions. It reduces pain and inflammation. Ask your doctor whether it is right for your condition.

How to use Espana 90

Swallow the tablet with water, as advised. Espana 90 is taken by mouth. If you are unsure how to take it, ask your doctor or pharmacist. The doctor decides the dose and how long you take it, based on your condition and health. Do not change the dose or stop on your own.

Side effects of Espana 90

Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight change, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle aches and joint pain. Rarely, confusion and hallucinations may occur. Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any effect troubles you.

Safety and precautions

People with active stomach ulcers or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammatory bowel disease, or a history of allergic reactions to aspirin or NSAIDs should not take it. Espana 90 90 mg tablet is not recommended during pregnancy or breastfeeding. Elderly people and those with stomach, heart or kidney risk factors need careful assessment. Keep out of reach of children.

Frequently asked questions

What does Espana 90 treat?

It does not treat the underlying disease; it relieves symptoms. Espana 90 is used for symptomatic relief in several painful and inflammatory conditions.

How do I use Espana 90 correctly?

Swallow the tablet with water, as advised. Espana 90 is taken by mouth.

What are the side effects of Espana 90?

Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight change, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle aches and joint pain. Rarely, confusion and hallucinations may occur.

Who should be careful with Espana 90?

People with active stomach ulcers or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammatory bowel disease, or a history of allergic reactions to aspirin or NSAIDs should not take it. Espana 90 90 mg tablet is not recommended during pregnancy or breastfeeding.

Indications

Etoricoxib is indicated for the symptomatic relief of-
  • Osteoarthritis (OA)
  • Rheumatoid arthritis (RA)
  • Ankylosing spondylitis, and
  • The pain and signs of inflammation associated with acute gouty arthritis.
  • For the short-term treatment of moderate pain associated with dental surgery.

Pharmacology

Etoricoxib is a potent, orally active cyclooxygenase-2 (COX-2) specific inhibitor within, and significantly above, the clinical dose range. Two isoforms of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for prostaglandin-mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Inhibition of COX-1 by nonselective NSAIDs has been associated with gastric damage and inhibition of platelet aggregation. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by etoricoxib (within the clinical dose range) decreases these clinical signs and symptoms with decreased potential for Gl toxicity and effects on platelet aggregation. Etoricoxib produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis.

Dosage & Administration

Adult and adolescent over 16 years:
  • Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy.
  • Rheumatoid arthritis: The recommended dose is 90 mg once daily.
  • Ankylosing spondylitis: The recommended dose is 90 mg once daily.
  • Acute gouty arthritis: The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, Etoricoxib was given for 8 days.
  • Postoperative dental surgery pain: The recommended dose is 90 mg once daily, limited to a maximum of 3 days.
Some patients may require additional postoperative analgesia. As the cardiovascular risks of Etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.

Interaction

With medicine:
  • Oral anticoagulants: In subjects stabilized on chronic warfarin therapy, the administration of Etoricoxib was associated with an increase in prothrombin time.
  • Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs.
  • Acetylsalicylic Acid: Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid).
  • Ciclosporin and tacrolimus: Although this interaction has not been studied with Etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus.
  • Lithium: NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels.
With food & others: Take without regards to meals.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients.
  • Active peptic ulceration or active gastro-intestinai (Gl) bleeding.
  • Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
  • Pregnancy and lactation.
  • Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 10).
  • Estimated renal creatinine clearance <30 ml/min.
  • Children and adolescents under 16 years of age.
  • Inflammatory bowel disease.
  • Congestive heart failure (NYHA ll-IV).
  • Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled.
  • Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

Side Effects

Side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations.

Pregnancy & Lactation

The use of Etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive. It is not known whether Etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use Etoricoxib must not breastfeed.

Precautions & Warnings

  • Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and Gl bleeding.
  • Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with Etoricoxib after careful consideration.
  • Administration of Etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Monitoring of renal function in such patients should be considered.
  • Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing edema from any other reason.
  • Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormalliver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, Etoricoxib should be discontinued.
  • Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
  • Etoricoxib may mask fever and other signs of inflammation. Caution should be exercised when co-administering Etoricoxib with warfarin or other oral anticoagulants.

Overdose Effects

Administration of single doses of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the Gl tract, employ clinical monitoring, and institute supportive therapy, if required.

Storage Conditions

Store at a temperature of below 30°C, protect from light & moisture. Keep out of reach of children.

Alternative brands of Etoricoxib

Other brands with the same generic name, cheapest first.

Eto Tablet

60 mg

Etoricoxib

Delta Pharma Limited

৳ 7.00 per unit

Rito Tablet

60 mg

Etoricoxib

Opsonin Pharma Limited

৳ 7.03 per unit

Coxia Tablet

60 mg

Etoricoxib

Advanced Chemical Industries PLC

৳ 7.05 per unit

See all 90 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.